Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Melisi

Showing results (21-30 of 128) with videos related to

Pageof 13
Sort By:
Therapeutic Advances in Medical Oncology|April 8, 2024
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bearDavide Melisi, Simona Casalino, Silvia Pietrobono, et al.
Biomedicines|May 27, 2017
Toll-Like Receptor 9 Agonists for Cancer TherapyDavide Melisi, Melissa Frizziero, Anna Tamburrino, et al.
Cancers|August 27, 2021
The Multifaceted Role of TGF-β in Gastrointestinal TumorsFabio Sabbadini, Monica Bertolini, Serena De Matteis, et al.
International Journal of Molecular Sciences|October 28, 2018
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and ChemoresistancePriscilla Cascetta, Alessandro Cavaliere, Geny Piro, et al.
International Journal of Molecular Sciences|February 2, 2018
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and CancerCarmine Carbone, Geny Piro, Valeria Merz, et al.
Future Oncology (London, England)|March 5, 2021
Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancerAlfredo Carrato, Davide Melisi, Gerald Prager, et al.
Molecular Cancer Research : MCR|May 14, 2009
Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaBDavide Melisi, Jiangong Niu, Zhe Chang, et al.
Expert Review of Anticancer Therapy|December 21, 2017
The development of PARP as a successful target for cancer therapyRoberto Ferrara, Francesca Simionato, Chiara Ciccarese, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|October 28, 2018
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled dataGiovanni Marchegiani, Stefano Andrianello, Chiara Dal Borgo, et al.
Cancers|May 6, 2020
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer PatientsValeria Merz, Alessandro Cavaliere, Carlo Messina, et al.
Pageof 13

Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Therapeutic Advances in Medical Oncology|April 8, 2024
Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bearDavide Melisi, Simona Casalino, Silvia Pietrobono, et al.
Biomedicines|May 27, 2017
Toll-Like Receptor 9 Agonists for Cancer TherapyDavide Melisi, Melissa Frizziero, Anna Tamburrino, et al.
Cancers|August 27, 2021
The Multifaceted Role of TGF-β in Gastrointestinal TumorsFabio Sabbadini, Monica Bertolini, Serena De Matteis, et al.
International Journal of Molecular Sciences|October 28, 2018
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and ChemoresistancePriscilla Cascetta, Alessandro Cavaliere, Geny Piro, et al.
International Journal of Molecular Sciences|February 2, 2018
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and CancerCarmine Carbone, Geny Piro, Valeria Merz, et al.
Future Oncology (London, England)|March 5, 2021
Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancerAlfredo Carrato, Davide Melisi, Gerald Prager, et al.
Molecular Cancer Research : MCR|May 14, 2009
Secreted interleukin-1alpha induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaBDavide Melisi, Jiangong Niu, Zhe Chang, et al.
Expert Review of Anticancer Therapy|December 21, 2017
The development of PARP as a successful target for cancer therapyRoberto Ferrara, Francesca Simionato, Chiara Ciccarese, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|October 28, 2018
Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled dataGiovanni Marchegiani, Stefano Andrianello, Chiara Dal Borgo, et al.
Cancers|May 6, 2020
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer PatientsValeria Merz, Alessandro Cavaliere, Carlo Messina, et al.
Pageof 13